[arista]

[Cherie]

Imperial pause trials on their vaccine to concentrate on tackling the variants

https://www.msn.com/en-gb/health/med...ts/ar-BB1d6LFa

cientists at Imperial College London have announced they will not be proceeding with large-scale testing of their Covid-19 vaccine because of the rapid approval of other jabs within the UK.

Professor Robin Shattock said his team would instead be using the RNA technology behind the vaccine to target new and emerging coronavirus variants that have been identified around the world.

“Although our first generation Covid-19 vaccine candidate is showing promise in early clinical development, the broader situation has changed with the rapid rollout of approved vaccines,” Prof Shattock said in a statement on Tuesday.

“It is not the right time to start a new efficacy trial for a further vaccine in the UK, with the emphasis rightly placed on mass vaccination in response to the rapid spread of the new variant.”

He said his team would begin working to develop the vaccine technology as “a safety net to catch escape mutations, reach variants that other vaccines may not, and meet potential needs for annual booster vaccinations”.

Similar in design to the Moderna and Pfizer/BioNTech vaccines, the Imperial College jab makes use of self-amplifying RNA to deliver genetic instructions to human muscle cells, which then go on to produce the spike protein found on the surface of Sars-CoV-2.

[Zizu]

Originally Posted by Cherie

Imperial pause trials on their vaccine to concentrate on tackling the variants



https://www.msn.com/en-gb/health/med...ts/ar-BB1d6LFa



cientists at Imperial College London have announced they will not be proceeding with large-scale testing of their Covid-19 vaccine because of the rapid approval of other jabs within the UK.



Professor Robin Shattock said his team would instead be using the RNA technology behind the vaccine to target new and emerging coronavirus variants that have been identified around the world.



“Although our first generation Covid-19 vaccine candidate is showing promise in early clinical development, the broader situation has changed with the rapid rollout of approved vaccines,” Prof Shattock said in a statement on Tuesday.



“It is not the right time to start a new efficacy trial for a further vaccine in the UK, with the emphasis rightly placed on mass vaccination in response to the rapid spread of the new variant.”



He said his team would begin working to develop the vaccine technology as “a safety net to catch escape mutations, reach variants that other vaccines may not, and meet potential needs for annual booster vaccinations”.



Similar in design to the Moderna and Pfizer/BioNTech vaccines, the Imperial College jab makes use of self-amplifying RNA to deliver genetic instructions to human muscle cells, which then go on to produce the spike protein found on the surface of Sars-CoV-2.

That sounds ominous ...


Sent from my iPhone using Tapatalk Pro

[Cherie]

Originally Posted by Zizu

That sounds ominous ...


Sent from my iPhone using Tapatalk Pro

makes sense? there are many vaccines on the go now so they lost the race with that one

[user104658]

Originally Posted by Zizu

That sounds ominous ...

It really doesn't, it sounds sensible . They're basically saying that they think there's enough vaccine "on the market" already so there's no point them adding another version to the pile that will more or less be just the same vaccine, so rather than wasting time on it they're moving on to other areas of study with the virus/vaccines.

[Nicky91]

Originally Posted by arista

the sheer irony there

EU's Ursula had said she wants the vaccines to be available for entire europe not just for eu countries